This Tender Offer Statement on Schedule TO (this “Schedule TO”) relates to the offer (the “Offer”) by Atlas Neon Merger Sub, Inc., a Delaware corporation (“Purchaser”) and a wholly owned subsidiary of Atlas Neon Parent, Inc., a Delaware corporation (“Parent”), to purchase all outstanding shares of common stock, par value $0.001 per share (the “Shares”), of NGM Biopharmaceuticals, Inc., a Delaware corporation (“NGM”), other than the Rollover Shares (as defined in the Offer to Purchase), for $1.55 per Share in cash (the “Offer Price”) upon the terms and subject to the conditions described in the Offer to Purchase and in the related Letter of Transmittal, copies of which are attached hereto as exhibits (a)(1)(A) and (a)(1)(B), respectively. The Offer is being made pursuant to the Agreement and Plan of Merger, dated as of February 25, 2024 (together with any amendments or supplements thereto, the “Merger Agreement”), among NGM, Parent and Purchaser, a copy of which is attached as Exhibit (d)(1) hereto and incorporated herein by reference with respect to Items 4 through 11 and 13 of this Schedule TO. Capitalized terms used but not otherwise defined herein have the meanings ascribed thereto in the Merger Agreement.
All of the information set forth in the Offer to Purchase is incorporated by reference herein in response to Items 1 through 9, Item 11 and Item 13 of this Schedule TO, and is supplemented by the information specifically provided in this Schedule TO.
ITEM 1.
| SUMMARY TERM SHEET. |
The information set forth in the section of the Offer to Purchase titled “Summary Term Sheet” is incorporated herein by reference.
ITEM 2.
| SUBJECT COMPANY INFORMATION. |
(a) The subject company and the issuer of the securities subject to the Offer is NGM Biopharmaceuticals, Inc. Its principal executive office is located at 333 Oyster Point Boulevard, South San Francisco, California 94080, and its telephone number is (650) 243-5555.
(b) This Schedule TO relates to the Shares. According to NGM, as of the close of business on March 1, 2024 there were: (i) 83,462,408 Shares issued and outstanding; (ii) 12,438,380 Shares subject to outstanding Company Stock Options, 7,344,505, of which were In-the-Money Options and (iii) 459,975 Shares subject to Company Restricted Stock Units.
(c) The information concerning the principal market on which the Shares are traded, and certain high and low sales prices for the Shares in the principal market in which the Shares are traded set forth in “Special Factors—Section 5. Price Range of Shares; Dividends” of the Offer to Purchase, are incorporated herein by reference.
ITEM 3.
| IDENTITY AND BACKGROUND OF FILING PERSON. |
(a)-(c) The filing persons of this Schedule TO are Parent, Purchaser, The Column Group, LP, The Column Group GP, LP, The Column Group II, LP, The Column Group II GP, LP, The Column Group Management, LP, Ponoi Capital, LP, Ponoi Management, LLC, Ponoi Capital II, LP, Ponoi II Management, LLC, The Column Group III, LP, The Column Group III-A, LP, The Column Group III GP, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group IV GP, LP, TCG IV GP, LLC, The Column Group Opportunity III, LP, The Column Group Opportunity III GP, LP, TCG Opportunity III GP, LLC, Peter Svennilson, David V. Goeddel and Timothy Kutzkey.
The Column Group GP, LP, The Column Group II GP, LP, Ponoi Management, LLC and Ponoi II Management, LLC are the general partners of The Column Group, LP, The Column Group II, LP, Ponoi Capital, LP and Ponoi Capital II, LP, respectively. The Column Group III GP, LP is the general partner of The Column Group III, LP and The Column Group III-A, LP. The Column Group IV, LP is the general partner of The Column Group IV, LP and The Column Group IV-A, LP, and TCG IV GP, LLC is the general partner of The Column Group IV, LP and the ultimate general partner of The Column Group IV, LP and The Column Group IV-A, LP. The Column Group Opportunity III GP, LP is the general partner of The Column Group Opportunity III, LP and TCG Opportunity III GP, LLC is the general partner of The Column Group Opportunity III GP, LP and the ultimate general partner of The Column Group Opportunity III, LP.
Mr. Svennilson and Dr. Goeddel are the managing partners of The Column Group GP, LP and The Column Group II GP, LP. Mr. Svennilson, Dr. Goeddel and Dr. Kutzkey are the managing members of Ponoi